TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04774016

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test formula A without added pre- and pro-biotic
Description: An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test formula B with synbiotic
Description: Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
Study: NCT04588649

Intervention type: DRUG
Group type: OTHER
Intervention: AV-45
Description: \[18F\]AV-45 PET Imaging
Study: NCT04774016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test formula C with HMOs
Description: Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
Study: NCT04078321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mollii ®
Description: The garment claims to have a 48 hours lasting effect of an hour of treatment. The garment should be worn for at least 1 hour every other day. All participants receive individually tailored garments and individually tailored appropriate training towards specific goals set in connection to study start. The garment is used in the home environment and the family is responsible for documentation of use in a diary. Measurements is performed following an ABAB design for four weeks. Measurement performed at 12 occasions during the four weeks are; spasticity, physical function, pain, sleep and adherence. Standardized protocols for the intervention are provided to involved physical therapists.
Study: NCT00668941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants will take 70 mg per week of alendronate for 48 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants will take 70 mg per week of alendronate for 48 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Participants will take 70 mg per week of alendronate for 48 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
Study: NCT00303719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of \>200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
Study: NCT02419820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel
Study: NCT00303719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of \>200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine 30 mg/m\^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m\^2 for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine 30 mg/m\^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m\^2 for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if \< 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) \> 0.5 x 109 /L).
Study: NCT02419820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel
Study: NCT00668941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
Study: NCT02419820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel
Study: NCT00668941

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
Study: NCT02419820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel
Study: NCT00668941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
Study: NCT00303719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if \< 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) \> 0.5 x 109 /L).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: The dose of TBI will be 200 cGy given in a single fraction on day -1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: The dose of TBI will be 200 cGy given in a single fraction on day -1.
Study: NCT02419820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin
Study: NCT00303719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Patients with white blood cell (WBC) counts \< 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) \> 2500 for 2 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Patients with white blood cell (WBC) counts \< 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) \> 2500 for 2 consecutive days.
Study: NCT00515866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: intravenous injection
Study: NCT03283813

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myoinositol
Description: In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
Study: NCT02275949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture
Description: Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock transcutaneous electrical nerve stimulation
Description: Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham intradermal acupuncture
Description: Intradermal acupuncture needles are put over the tape not penetrating the skin.
Study: NCT00668941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
Study: NCT02419820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for APD791
Description: Placebo for APD791
Study: NCT00402961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
Study: NCT03103789

Intervention type: DIAGNOSTIC_TEST
Intervention: single catheter mucosal impedance testing

Intervention type: DIAGNOSTIC_TEST
Intervention: single catheter mucosal impedance testing
Study: NCT02419820

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for APD791
Description: Placebo for APD791
Study: NCT03044808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT03103789

Intervention type: DIAGNOSTIC_TEST
Intervention: balloon assembly mucosal impedance testing

Intervention type: DIAGNOSTIC_TEST
Intervention: balloon assembly mucosal impedance testing
Study: NCT01147861

Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: 5mg in the AM and 5mg in the PM

Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: 10mg in the AM

Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: 50mg in the AM

Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: 25mg in the AM and 25mg in the PM
Study: NCT03044808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02927938

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic HCT
Description: Allogeneic HCT

Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation chemotherapy
Description: Cytarabine-based consolidation chemotherapy
Study: NCT04129892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In Favor of My Resilient Self Academic course
Description: Assessing the effect of an academic course on student's emotional resilience.
Study: NCT02468349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
Study: NCT02199561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal transplant processed from routinely screened universal donor
Study: NCT02340910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short Duration
Description: During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long Duration
Description: During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks .
Study: NCT02653547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard multisite four weeks
Description: Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-frequency multisite four weeks
Description: Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
Study: NCT01147861

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets in the AM and 2 placebo tablets in the PM
Study: NCT03406858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2Bi-Armed Activated T Cells
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04945629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation with a PRP (PRGF-Endoret)
Description: Filling of the alveolus with PRGF clot and fibrin plug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blood clot and simple suture
Description: Filling the alveolus with blood clot
Study: NCT02248350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised and Home Based Exercise
Description: Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Control Group
Description: Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
Study: NCT02881242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT02672423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib Capsules (Reference Formulation)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib Capsules (Reference Formulation)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib Tablet (Test Formulation)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib Tablet (Test Formulation)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib Tablet (Test Formulation)
Description: Administered orally
Study: NCT03832621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 480 mg i.v. every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
Study: NCT03936361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH